EU Issues New Guidance for Conducting Clinical Trials During Public Health Emergencies

The EMA has released new guidance designed to support the rapid and effective conduct of clinical trials during public health emergencies across the EU.

The guidance aims to help researchers, regulators, and pharmaceutical companies generate reliable evidence on new treatments and vaccines when urgent health threats emerge.

Lessons From the COVID‑19 Pandemic

The recommendations were developed following lessons learned during the global response when clinical trials had to be organized quickly while maintaining strict scientific and ethical standards.

Regulators noted that faster coordination between research institutions, governments, and healthcare systems is essential to ensure that effective therapies can be evaluated and made available to patients as quickly as possible during crises.

Key Features of the New Guidance

The guidance outlines several measures aimed at improving preparedness and efficiency in emergency research settings. These include:

• Encouraging large, multi‑country clinical trials to generate stronger evidence.
• Promoting simplified regulatory procedures during emergencies.
• Strengthening collaboration between national authorities and international research networks.
• Ensuring patient safety and ethical oversight remain central to all trial activities.

Improving Europe’s Emergency Preparedness:

According to the EMA, the framework will help the EU respond more effectively to future public health crises by enabling researchers to launch coordinated trials more quickly.

Officials say the approach could accelerate the development and evaluation of vaccines, medicines, and other medical interventions when new infectious diseases or health threats emerge.

The agency also emphasized the importance of transparency, data sharing, and international cooperation to ensure that research findings can guide global public health responses.